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Electrocardiographic imaging (ECGI) reconstructs the electrical activity of the heart
from a dense array of body-surface electrocardiograms and a patient-specific heart-
torso geometry. Depending on how it is formulated, ECGI allows the reconstruction
of the activation and recovery sequence of the heart, the origin of premature
beats or tachycardia, the anchors/hotspots of re-entrant arrhythmias and other
electrophysiological quantities of interest. Importantly, these quantities are directly and
non-invasively reconstructed in a digitized model of the patient’s three-dimensional
heart, which has led to clinical interest in ECGI’s ability to personalize diagnosis and
guide therapy. Despite considerable development over the last decades, validation of
ECGI is challenging. Firstly, results depend considerably on implementation choices,
which are necessary to deal with ECGI’s ill-posed character. Secondly, it is challenging
to obtain (invasive) ground truth data of high quality. In this review, we discuss the
current status of ECGI validation as well as the major challenges remaining for complete
adoption of ECGI in clinical practice. Specifically, showing clinical benefit is essential for
the adoption of ECGI. Such benefit may lie in patient outcome improvement, workflow
improvement, or cost reduction. Future studies should focus on these aspects to
achieve broad adoption of ECGI, but only after the technical challenges have been
solved for that specific application/pathology. We propose ‘best’ practices for technical
validation and highlight collaborative efforts recently organized in this field. Continued
interaction between engineers, basic scientists, and physicians remains essential to
find a hybrid between technical achievements, pathological mechanisms insights, and
clinical benefit, to evolve this powerful technique toward a useful role in clinical practice.
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INTRODUCTION
Electrocardiographic imaging (ECGI) reconstructs the electrical
activity of the heart from a dense array of body-surface
electrocardiograms and a patient-specific heart-torso geometry.
Depending on how the problem is formulated, ECGI allows
the reconstruction of the activation and recovery sequence
of the heart, the origin of premature beats or tachycardia,
the anchors/hotspots of re-entrant arrhythmias and other
electrophysiological quantities of interest. Importantly, these
quantities are directly and non-invasively reconstructed in a
digitized model of the patient’s three-dimensional heart, which
allows personalized diagnosis and localized therapy guidance.
Over the past four decades, ECGI has seen considerable
development, from purely analytical studies (Rudy et al., 1979;
Figuera et al., 2016; Svehlikova et al., 2018), to torso tank (Oster
et al., 1997, 1998; Ramanathan and Rudy, 2001; Shome and
Macleod, 2007; Bear et al., 2018a) and large animal models (Liu
et al., 2012; Oosterhoff et al., 2016; Cluitmans et al., 2017; Bear
et al., 2018b) and finally application in humans (Ghanem et al.,
2005; Horácˇek et al., 2011; Haissaguerre et al., 2014; Schulze,
2015; Punshchykova et al., 2016). It is now increasingly used for
academic research and in clinical practice. Despite this progress,
validation of ECGI remains a significant challenge.
Mathematically, ECGI solves the inverse problem of
electrocardiography (i.e., to determine the cardiac electrical
source for a given body-surface potential distribution), a
problem fundamentally hindered by the fact that a multitude
of patterns of cardiac electrical activity can produce similar
body-surface potentials. The majority of these “inverse solutions”
are physically and physiologically unlikely; therefore, additional
constraints are imposed to stabilize the problem and select a
more realistic solution, a process that is called “regularization.”
Regularization that is based on physical and physiological a priori
information significantly improves the solvability and robustness
of inverse solutions from ECG recordings. ECGI is thus strongly
dependent on implementation choices, such as the cardiac source
model and the method of regularization. Both these components
need to be taken into account by the validation approach,
which is not always straightforward. A second aspect that makes
ECGI validation challenging is the difficulty in obtaining highly
detailed and localized invasive ground-truth data in in vivo
animals or humans. Finally, ECGI is strongly dependent on
the specific clinical application of interest, as each application
will yield a need for different quantitative parameters and their
validation.
The aims of this paper are:
(1) To review the current status of validation of ECGI, as
recent overviews on this topic are lacking (Sections Forms
of Validation, Cardiac Source Models, Technical Validation,
Pathological Validation, and Clinical (and Socioeconomic)
Validation);
(2) To highlight which challenges in ECGI validation remain
to facilitate clinical adoption; this includes commercial
and socioeconomic challenges (Section Clinical (and
Socioeconomic) Validation);
(3) To provide a consensus on the “best” ways to perform ECGI
validation in the future (Section Consensus on Designing a
Validation Study).
FORMS OF VALIDATION
Given the increased clinical use of ECGI over the recent past,
there is an associated need for ECGI validation. Validation studies
come in three different forms: technical, pathological, or clinical
validation (see Figure 1).
The first form evaluates the technical accuracy and
performance of ECGI for reconstructing the value of specific
electrophysiological quantities. The relevant quantities include
transmembrane voltage, electrograms, activation and recovery
times, and related features that can be quantified. The accuracy
of these features is not only influenced by the inverse or
regularization methods that are used, but also by the pre-
processing (e.g., techniques that filter or average the recorded
body-surface potentials or improve the geometrical accuracy,
methods to deal with poor quality signals, etc.) and post-
processing methods that are used to extract features that are not
directly available from inverse solutions (e.g., the calculation of
activation time or other temporal fiducials from a reconstructed
electrogram, or the use of phase mapping for rotor detection).
Technical validation studies seek to evaluate these quantifiable
features, generally irrespective of the underlying disease or
clinical setting.
The second category of ECGI validation studies is to define
the pathological accuracy and performance of ECGI, i.e., its
capability to extract features applicable to a specific pathology or
arrhythmia. For example, determining the origin of a premature
ventricular complex (PVC) requires a different approach than
determining the fractionation of local electrograms in myocardial
infarction, or determining the region of large repolarization
gradients in patients susceptible to ventricular fibrillation (VF).
For each of these types of validation, the exact value of the
reconstructed quantities may not be as important as their ability
to separate healthy from diseased states. For example, it may
matter less whether ECGI can determine the exact value of the
steepness of a repolarization gradient (which, for example, may
depend on mesh coarseness) as long as it can reliably differentiate
a proarrhythmic gradient from a normal gradient (Vijayakumar
et al., 2014).
The third category of validation studies evaluates the clinical
accuracy and performance of ECGI, i.e., its benefit in daily clinical
practice. The main focus of these studies is not the accuracy of
reconstructed or post-processed parameters, but their influence
on clinical decision making. For example, ECGI might provide
improved therapy outcomes in atrial fibrillation (AF) ablation,
improved workflow in the cardiac electrophysiology laboratory,
reduced radiation burden or procedural times, etc.
Although we divide validation into three distinct categories,
there is often overlap between them, particularly in the case
of “pathological” and “clinical” validation. Here we used these
categories to emphasize the difference between using ECGI
to investigate disease mechanisms (in which validation may
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FIGURE 1 | Describes the validation continuum, from purely technical studies to pathological/clinical validation and socioeconomic benefit studies. Whereas the
technical validation of ECGI is extensive, as is its use in disease mechanisms studies and validation of the true clinical benefit is still lacking.
focus on parameters directly reconstructed by ECGI) and using
ECGI for clinical applications (in which validation may focus
on indirect parameters such as patient outcome and reduced
procedure costs).
Each validation form has different requirements in terms of
data, metrics and analysis (Figure 1). In the remainder of this
review, we assess the current status of each validation form,
discuss the different issues surrounding validation, and provide
a consensus as to the best approach to overcome these challenges
to arrive at clinically relevant studies and applications.
CARDIAC SOURCE MODELS
Validating an ECGI formulation begins by defining the cardiac
source to be reconstructed. Many of the original ECGI
formulations approximated the cardiac source as either a single
or multiple equivalent dipoles (Bayley and Berry, 1962; Rudy
and Messinger-Rapport, 1988) or equivalent dipole layer (van
Oosterom, 2004). Despite these source models being “equivalent”
to the “ground truth” cardiac electrical activity they represent
(in the sense that the models each fully represent cardiac
electrical activity from a biophysical standpoint), there are no
obvious physiological links, making experimental and/or clinical
validation difficult.
Figure 2 illustrates the three current predominant cardiac
source models and the features that can be derived from them:
transmembrane voltage-based models, extracellular-potential
based models, and activation/recovery-based models. The
definition of an appropriate ground truth for comparison among
these cardiac source models can be difficult, particularly when
using experimental or clinical data sets. Often, investigators need
to be satisfied with a derived ground truth data (e.g., activation
times) or a ground truth hampered by error due to experimental
limitations.
Transmembrane Voltage-Based Model
Taking the transmembrane voltage (TMV, i.e., the potential
difference across the cell membrane of a cardiomyocyte, or a
continuum approximation of that quantity), as a cardiac source
model is the closest approximation to the true cardiac electrical
source. Transmural reconstructions of TMV are possible (He
et al., 2003; Wang et al., 2010; Potyagaylo et al., 2012), but a
reformulation from Geselowitz (assuming equal anisotropy ratios
of intracellular and extracellular conductivity tensors) also allows
for a reconstruction of TMV on the endo- and epicardial surfaces
(Simms and Geselowitz, 1995).
Reconstructions of TMV support identification of depolarized
and repolarized regions in the heart and their temporal
evolution. They also have the ability to outline areas of reduced
amplitude, or completely absent TMV, e.g., ischemic, fibrotic,
or border-zone areas. However, TMVs cannot be measured
directly in the clinical environment, and thus any validation
has to occur indirectly via the extracellular signals that TMV
distributions create. Extracellular potentials on the endocardial
and epicardial surfaces and activation and recovery times can
easily be calculated from TMV distributions and then measured
in experiments.
Impressed currents (i.e., the gradient of the TMV multiplied
by the intracellular conductivity) can also be seen as sources
of electrophysiological signals. In the original formulation,
the impressed currents are vector fields, thus increasing the
number of unknown properties by a factor of three. Thus, some
studies propose to reconstruct only the normal or the tangential
component of the impressed currents (Grace et al., 2017). For
the case of equal anisotropy ratios of conductivity, the impressed
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FIGURE 2 | Electrocardiographic imaging requires recording of body-surface potentials and the acquisition of a torso-heart geometry through computed
tomography (CT) or magnetic resonance (MR) imaging. The electrical characteristics of the heart can then be computed by employing one of the “source models,”
i.e., models of cardiac electrical activity that explain the recorded body-surface potentials. Globally, these source models are categorized as: transmembrane voltage
(TMV) models, surface-potential models (either epicardial-only or endo-epicardial surface), and activation/recovery-based models. It is possible to compute surface
potentials and electrograms from TMVs, and to compute activation and recovery sequences from electrograms, but not the other way around. Image in part
reproduced with permission from: Cluitmans (2016); Weiss et al. (2007), and Van Dam et al. (2009).
currents can also be replaced by an equivalent dipole layer with
equivalent current density distributions orthogonal to the surface
of the heart (Janssen et al., 2017) (also see the EDL model in
Section Activation/Recovery-Based Models).
An advantage of TMV or impressed current based solutions is
that a priori physiological knowledge about the action potential
propagation, available through various mathematical models, can
be used to constrain the reconstruction. The challenge in terms of
validation, on the other hand, is that TMVs or impressed currents
are difficult to obtain experimentally or clinically.
Extracellular Potential-Based Model
Potential-based models represent the cardiac source using
extracellular potentials on the heart surface. There are several
possible definitions of this cardiac surface, typically including
only the ventricular or atrial cavities. The most common
definition uses the epicardial surface, often artificially closed
across the valves and the base. The surface can also be defined
as both the endocardium and epicardium, leaving an opening
at the valves. Both versions are presented for the ventricles in
Figure 2. The key requirement for most methods is that the
surface encompasses all active electrical sources.
Two key features are directly available from a potential-based
model: electrograms and potential maps. Cardiac electrograms
are the change in potential over time at a single point on the
heart, and potential maps show the potential distribution over
the surface at a specific time point. One benefit of potential-based
models in terms of validation is that these features are much
more easily measurable than TMVs and can be recorded during
experimental or catheter-based procedures, even in humans.
Moreover, like TMVs, additional information contained within
the electrograms, such as activation and recovery processes,
can be extracted through post-processing. On the other hand,
while potential-based models can provide information on both
epicardial and endocardial surfaces (Rudy and Burnes, 1999),
direct reconstruction of transmural propagation is currently not
possible. Importantly, many potential-based implementations
of ECGI only provide epicardial reconstructions, without
endocardial or septal potentials. In general, the extracellular
approach (formulated either just epicardial or endocardial and
epicardial) is the basis of some commercial systems and as such
may currently have the highest clinical relevance of all source
formulations.
Activation/Recovery-Based Models
The purpose of activation/recovery-time based models is to
obtain the local times of activation or recovery directly,
without reconstruction of TMVs or extracellular potentials
as intermediate. As such they provide a highly stylized,
simplified sparse parameterization that captures key aspects of
the underlying biophysics. Activation times are described as
the time of arrival of the depolarization phase of an action
potential. Similarly, recovery times capture the timing of the
repolarization phase. Both quantities can be defined either
through the 3-dimensional (3D) myocardial wall (Han et al.,
2011), or on the heart surface, including both the epicardium
and endocardium (Erem et al., 2014). Examples of such methods
include the equivalent double layer (EDL) model and the 3D
cardiac electrical imaging (3DCEI) model:
• Equivalent Double Layer Model (EDL)
The macroscopic EDL model (Van Oosterom, 2001)
represents the entire electrical activity of the atria
or ventricles at any time instant (van Oosterom and
Jacquemet, 2005a). This source model stems from the
classic bioelectrical double layer as an equivalent source
of the currents generated at the boundary between active
and resting cells during depolarization, described by Wilson
et al. (1933). Initially, this current dipole layer model was
used to describe the activity at the front of a depolarization
wave propagating through the myocardium. Later, Salu
expressed the equivalence between the double layer at the
wave front and a uniform double layer at the depolarized
part of the surface bounding the myocardium (Salu, 1978),
based on solid angle theory (van Oosterom, 2002) (see
Figure 2). Later, Geselowitz showed, using a bidomain
model, that the actual current source distribution within
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the heart is equivalent to a double layer at the surface
of the myocardium with a strength proportional to the
local TMV (Geselowitz, 1989, 1992; van Oosterom and
Jacquemet, 2005b). The waveform of the TMV at each
location on the myocardial surface (both endocardium
and epicardium) is described by at least two parameters:
the local activation and recovery times. Consequently, the
source parameters of the EDL model also consist of the
activation and recovery times. More complex versions allow
as many as seven parameters (van Oosterom, 2004). One
challenge of this model is that the relationship between the
source parameters and the source strength is non-linear.
• 3D Cardiac Electrical Imaging (3DCEI)
While the EDL model allows estimating activation or
recovery times over the heart surface (including both
epicardium and endocardium), the 3DCEI model aims
to reconstruct cardiac activation and recovery process
throughout the entire 3D myocardium – including
epicardium, endocardium, and intramural tissues
(MacLeod et al., 2000; He et al., 2003). While 3DCEI is
applicable to both ventricles and atria, its main application
is for imaging the ventricular activation sequence (Han
et al., 2011) from the inversely reconstructed equivalent
current densities (He and Wu, 2001), or imaging the
ventricular repolarization process through reconstruction
of the activation-repolarization interval at each point within
the 3D ventricles (Wang et al., 2013). The relationship
between cardiac equivalent current density and local
activation time is established based on the “peak criteria”
reflecting the fundamental biophysics of cardiac activation
(MacLeod et al., 2000). This model has been evaluated
extensively in in vivo animal models with simultaneous
3D intracardiac mapping in rabbits (Han et al., 2011;
Duchateau et al., 2016) and in dogs (Cluitmans et al., 2017),
as well in scarred myocardial tissue (Wang et al., 2013).
To solve the inverse problem using these source models
usually requires an initial estimate of the activation and recovery
times, which is then improved through numerical iteration. An
advantage of these approaches is that a priori physiological
knowledge can be used to obtain very reasonable initial activation
and recovery times (Van Dam et al., 2009), thus reducing
convergence time and improving accuracy. At the same time, it
remains unclear how well the models perform when assumptions
of the underlying physiology are violated, e.g., when scar tissue
is present but is not incorporated in the model (Erem et al.,
2014). For normal healthy subjects and patients with idiopathic
PVC, this method has been shown to work well (Van Dam et al.,
2009). Current research focuses on developing initial estimate
algorithms that deal with inhomogeneous cardiac activation, e.g.,
when scar tissue is present.
TECHNICAL VALIDATION
Technical validation of ECGI is the most quantitative validation
approach, explicitly comparing the ECGI reconstruction to
ground truth to determine its absolute accuracy irrespective
of the underlying pathology. Technical validation encompasses
a broad range of cardiac source models, forward model
formulations, inverse methods, and pre- and post-processing
techniques. These studies are typically executed using either
analytical (Rudy et al., 1979) or simulated potentials (Dubois
et al., 2016; Figuera et al., 2016; Svehlikova et al., 2018),
ex vivo torso tank experiments (Oster et al., 1997; Shome and
Macleod, 2007; Bear et al., 2018a) and in vivo animal studies
(Liu et al., 2012; Oosterhoff et al., 2016; Cluitmans et al., 2017;
Bear et al., 2018b), with more limited results from humans
(Ghanem et al., 2005; Sapp et al., 2012; Erem et al., 2014; Schulze,
2015; Punshchykova et al., 2016). For simplicity, here we have
organized technical validation according to the different features
that may be extracted from ECGI, irrespective of source models.
These features provide scientists and clinicians with information
about cardiac electrical activity and can either be provided
directly by the cardiac source model chosen (i.e., electrograms
when using a potential-based approach) or extracted through
further post-processing of the ECGI-reconstructed signals (i.e.,
activation or phase mapping from electrograms), as summarized
in Figure 2.
Transmembrane Voltages
While validation of reconstructed TMVs is possible using
simulated data, it is nearly impossible experimentally and
clinically as the ground truth data can only be obtained through
optical mapping, monophasic action potentials recording, or
patch clamping. These are all techniques that are currently
difficult to obtain in vivo and the latter two are infeasible
over more than a very few sites in a whole heart. If these
data are available, they serve as the optimal approach for
comparing magnitude and shape of different phases, particularly
depolarization and repolarization. If these data are not available,
the focus of validation shifts to post-processed values of
TMPs, such as unipolar electrogram morphology, activation and
recovery isochrones, etc.
Electrograms
Electrograms are one of the most common features reconstructed
with ECGI, as they provide useful information to clinicians,
directly relatable to invasive recordings. Ground truth data is
available through simulations (Simms and Geselowitz, 1995;
Wang et al., 2010; Figuera et al., 2016; Janssen et al., 2017),
recordings obtained with epicardial, endocardial and transmural
electrode arrays (with upwards of 200 electrodes) in ex vivo
(Oster et al., 1997; Shome and Macleod, 2007; Bear et al., 2018b)
and in vivo (Zhang et al., 2005; Han et al., 2011; Liu et al.,
2012; Oosterhoff et al., 2016; Cluitmans et al., 2017; Bear et al.,
2018b) experimental models, and invasive mapping clinically
(Ghanem et al., 2005; Sapp et al., 2012; Punshchykova et al.,
2016). Most validation studies to date use a global evaluation
of the QRS, T, or QRS-T waveform reconstruction using
correlation and/or error metrics, to demonstrate the accuracy
in the overall topology and/or amplitude of electrograms
(example in Figure 3). Persistent challenges include assessing
spatial accuracy (Cluitmans et al., 2017; Bear et al., 2018b)
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FIGURE 3 | Top: epicardial geometry with reconstructed potentials from a canine in vivo study, for a sinus beat (A) and a LV-paced beat (B). White dots indicate the
position of invasive electrodes used for validation recordings. Bottom: recorded (red) and ECGI-reconstructed (black) electrograms for electrodes numbered in
geometry above. CC, correlation coefficient between recorded and reconstructed electrograms. RA, right atrijm; RV, right ventricle. Adapted with permission from
Cluitmans et al. (2017).
and the sensitivity of results to different sources of error,
i.e., cardiac motion (MacLeod et al., 2000; Cluitmans et al.,
2017). To date, while qualitative assessment of reconstructed
electrograms is often described, comprehensive quantification of
the presence/absence of detailed characteristics in reconstructed
electrograms has never been performed, including fractionation,
low/high amplitudes, epicardial/endocardial source, ST-
segment elevation, etc. The inaccurate reconstruction of these
characteristics is often missed using a global evaluation. Metrics
to quantify the presence of such local features are needed
as this information can be critical to the diagnosis and/or
treatment of particular pathologies (see Section Metrics for
Validation).
Unipolar electrograms on the cardiac surface are influenced
by what are known as “far-field” effects from electrical activity
in other parts of the myocardium, this influence varying with
electrode size and filtering techniques. Since ECGI electrogram
reconstructions may be even more sensitive to such effects given
the ill-posedness of the inverse problem, care is required in
interpreting validation results, especially if the surface model does
not include the endocardium or if validation measurements are
only available on either the endo- or the epicardium.
Potential Maps
In addition to electrograms, potentials can be visualized spatially
as potential maps that vary in time. Hence, validation is often
performed using the same data set as for electrograms through
global quantitative comparisons of reconstructed potential maps
to the ground truth signals, using correlation and error metrics
over time (Oster et al., 1997; Bear et al., 2018b). One limitation of
quantitative comparison is that during the early and late phases
of activation, only small regions of the heart are activated, leading
to distorted values of signal-to-noise and global error metrics (see
Figure 4). It remains unclear if specific characteristics during
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FIGURE 4 | Epicardial potential maps derived from ECGI (left) and recorded (right) epicardial electrograms at three instants during ventricular activation during
epicardial pacing from the anterior RV free wall (ECG shown left). During the early and late phases of activation, only small regions of the heart are activated, leading
to distorted values of error metrics such as correlation (right, showing different reconstruction approaches in different colors). Adapted with permission from Bear
et al. (2018b).
these time periods can be accurately reconstructed, such as the
initial site of activation (based on the location of epicardial
deepest negative potential) or regions of current sources (similar
to ST segment elevation). However, potential maps are only
beginning to be used in clinical practice (Jamil-Copley et al.,
2015) and assessment of individual electrograms for signal
amplitude, activation time or specific characteristics is currently
more clinically practical.
Activation/Recovery Maps
Activation and recovery time maps provide very
useful static isochrone images of the cardiac electrical
depolarization/repolarization sequence. These isochrones
may be used clinically to identify several quantities: (a) sites
of initiation of activation by focal arrhythmias, e.g., premature
ventricular contraction (PVC) origin; (b) delineation of reentry
circuits, e.g., macroreentrant atrial flutter (Shah et al., 1997),
or (c) abnormalities in propagation, such as areas with delayed
activation (Irie et al., 2015), or those with slow or abnormal
conduction, e.g., scar-related ventricular tachycardia substrate,
or (d) areas with recovery abnormalities, e.g., large recovery
gradients (Vijayakumar et al., 2014; Leong et al., 2017). To
date, the majority of validation studies have concentrated on
the accuracy of activation mapping (Oster et al., 1997; Zhang
et al., 2005; Han et al., 2011; Oosterhoff et al., 2016; Bear et al.,
2018b), with only a few studies assessing recovery (Van Dam
et al., 2009; Cluitmans et al., 2017). The earliest site of activation
of paced beats is often reconstructed and compared to the known
location of pacing, yielding a localization error. For example,
animal validation studies with pacing localization exist for
potential-based (Cluitmans et al., 2017; Bear et al., 2018b) and
activation/recovery-based approaches (Han et al., 2011; Liu et al.,
2012; Oosterhoff et al., 2016).
Apart from beat origins, validation studies of activation- and
recovery-time maps tend to assess global accuracy, providing
correlation and relative error metrics. This approach may
overlook other characteristics/abnormalities, such as steepness
of recovery gradients, or the presence/absence of conduction
block or localized changes in velocity of activation (conduction).
One study (Bear et al., 2018a) has recently demonstrated that
in left bundle branch block, ECGI can compress local activation
to create an artifactual “line of block,” which is not reflected in
correlation values (Figure 5).
One of the difficulties in activation/recovery map validation
is the need to derive the activation/recovery times from
electrograms and thus their dependence on the signal processing
method used. Most applications use the gold standard method for
deriving activation/recovery times from directly recorded signals
(defined as the time of minimum and maximum derivatives,
respectively, of the unipolar electrogram). However, these gold
standard methods are typically imprecise, both for actual
recordings and for ECGI-derived electrograms, and alternative
methods may be required (Erem et al., 2011; Duchateau
et al., 2016; Cluitmans et al., 2017). These methodology-linked
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FIGURE 5 | Validation of ECGI derived activation maps using an ex vivo torso
tank set up has demonstrated that, in electrical dyssynchrony, ECGi (right)
produces a “line of activation block” that is not present in recorded signals
(left) using an epicardial electrode sock [adapted with permission from Bear
et al. (2018a)].
variations in derivations of activation/recovery times may impact
overall performance estimate.
Phase Maps
Phase is a feature that was initially designed to decompose action
potential signals, the basic concept being to discard amplitude
and focus on the temporal sequence (resting state, activation,
refractory period, and repolarization). Between two consecutive
activations of the tissue, the phase will increase in a monotonic
way from−pi to+pi (or from 0 to 2pi if preferred). When applied
to optical mapping recordings of complex cardiac arrhythmia
(atrial and VF), phase is an effective feature in analyzing
spatiotemporal organization (Gray et al., 1996). The spatial
representation of the instantaneous phase allows one to identify
focal activity and/or local reentry using features computed
directly from the spatial organization of the phase signal (phase
divergence and phase singularities). Such representations have
sparked clinical interest in using phase mapping on electrical
recordings as a means of detecting organized stable drivers during
fibrillation, and potentially target them for ablation therapy
(Umapathy et al., 2010; Narayan et al., 2012; Haissaguerre et al.,
2013).
An efficient tool commonly used to convert time-varying
signals from the voltage domain to the phase domain is the
Hilbert Transform. This conversion from voltage to phase
does not meet the objective of having a monotonic signal
that ranges from −pi to +pi (or in general an interval of
2 pi) between two consecutive cycles for signals with multiple
deflections, such as bipolar or noisy electrograms. For this
reason, electrograms are typically smoothed prior to conversion.
Depending on the filtering chosen for the preprocessing step,
the resulting phase maps may lead to over/under-estimation of
the extent of re-entrant cycles (Rodrigo et al., 2017). The lack
of methodological consensus on both the preprocessing and the
definition of spatially or temporally stable phase singularities
has resulted in ongoing debate over phase mapping techniques
(Vijayakumar et al., 2016; Kuklik et al., 2017). To minimize
such ambiguities, it is advisable to incorporate electrogram
characteristics and the time-domain activation sequence into the
analysis (as demonstrated in Figure 6).
Though applicable to the ventricles (Umapathy et al., 2010),
contemporary ECGI applications are most commonly atria based,
with validation using some clinical patient data (Metzner et al.,
2017) and, more extensively, simulated data (Dubois et al., 2016;
Figuera et al., 2016; Pedrón-Torrecilla et al., 2016; Kuklik et al.,
2017; Rodrigo et al., 2017). Validation using experimental data
is still needed. Phase can be validated in a similar manner to
electrograms, using correlation and relative error to assess the
global topology of the phase signals. However, phase signals
at a particular electrode are themselves not of clinical interest,
but rather the spatial distribution and temporal evolution
of phase that allows the detection of divergence/singularity
points. As such, in addition to correlation and relative error,
we support the use of error metrics that assess localization
accuracy of the divergence/singularity points or derived maps,
such as the weighted under-estimation or the weighted over-
estimation indicators (Figuera et al., 2016). Another useful
approach entails computing the Phase Locking Value (PLV),
which estimates the synchronicity between two signals, without
regard to the constant phase shift between them (Dubois et al.,
2016).
Dominant Frequency
In addition to phase, frequency is often used in the analysis
of atrial and VF, where localized sites of high (or dominant)
frequency (DF) serve as target ablation sites to eliminate AF
(Sanders et al., 2005) (as seen in Figure 6). Because the
conventional computation of frequency is done over a time
segment, DF produces time-averaged frequency information over
space. An absence in stability of the arrhythmia can lead to errors
in DF estimation. Metrics to assess stability can be computed,
such as the regularity (Everett et al., 2001; Sanders et al., 2005;
Sánchez et al., 2017), organization, or coupling indices (Faes
and Ravelli, 2007) and they indicate whether the activation is
regular/periodic. Sequential analysis can be used to track the
movement and determine the stability of DF sites over time
(Salinet et al., 2014). In addition, the presence of shape-related
and not only rhythm-related DF components can result in
incorrect identification of the activation rates in the atria. As with
phase, studies have reported controversial results, likely due to
the different approaches for signal processing, DF computation,
and interpretation. We refer readers to a review by Ng et al.
(2007). That explores the technical requirements and limitations
of dominant frequency analysis of AF signals.
Like phase mapping, current technical validation of ECGI
derived dominant frequency has been limited to the atria and
to the use of endocardial mapping measurements (Pedrón-
Torrecilla et al., 2016; Zhou et al., 2016) and simulations (Figuera
et al., 2016; Rodrigo et al., 2017) to provide ground truth data.
Validation of frequency-based estimates can be performed using
relative or absolute error, correlation to assess the global map
distribution, and, more importantly, error metrics to assess
localization of the region of dominant frequency, e.g., direction
of DF gradient, either from left atrium to the right atrium,
or weighted under/over-estimator indicators (Figuera et al.,
2016), as well as other metrics that may be derived such as
regularity/organization indexes.
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FIGURE 6 | During atrial (AF) or ventricular fibrillation, the mechanism of fibrillation can be assessed using phase and/or frequency mapping. (A) [adapted with
permission from Haissaguerre et al. (2014)], ECGI derived phase maps of ≥1000-ms-long AF window show reentry events involving the posterior upper right atrium;
sites 1–12 show the pre-phase electrograms around its core. By tracking phase singularities (PS) for reentrant activity of at least one full rotation, PS density maps
illustrate arrhythmogenic drivers that may be targets for ablation. (B) [adapted with permission from Pedrón-Torrecilla et al. (2016)], dominant frequency (DF) using
invasive CARTO (top) and non-invasive ECGI (bottom) in AF patients demonstrate good correspondence. Region of high DF (purple) identify arrhythmogenic drivers
that may be targets for ablation.
PATHOLOGICAL VALIDATION
The major goal of ECGI is to be useful as a clinical tool to
aid in diagnosis and therapy planning of specific pathologies
and/or arrhythmias by identifying the mechanisms underlying
these electrical disorders and their response to therapy. As
such, validation of ECGI to extract the information applicable
to a specific pathology/arrhythmia is essential. As mentioned
previously, the quantitative accuracy of the reconstructed
quantities may not be as important as their ability to separate
healthy and diseased states. However, ECGI needs to be accurate
enough to ensure that conclusions drawn from specific features
are not actually a misinterpretation of artifacts in the solution.
Moreover, clinicians typically want insight into the characteristics
of a pathology and not just a binary classification. Such depth
and detail are particularly important because conclusions drawn
from ECGI can lead to the identification and implementation
of costly, and potentially life-saving, treatment plans, such as
guiding ablation therapy or implanting ICD or CRT devices.
Here we identify some pathologies and/or arrhythmias for
which ECGI may be applicable, along with associated features
desired for clinical applications. For a summary of the results
from previous ECGI studies of arrhythmogenic substrates, we
refer the reader to the review by Rudy (2013).
Atrial Arrhythmias
One of the first extensively clinically explored applications of
ECGI was to identify the specific mechanisms of arrhythmia
onset and/or maintenance for ablation therapy in atrial
tachycardia (AT) and fibrillation (AF). ECGI is currently
used to determine the specific patterns underlying activation
during arrhythmia (i.e., focal vs. re-entrant) through phase
mapping (Cuculich et al., 2010; Roten et al., 2012) and
to localize the drivers of this activation using either the
estimated dominant frequency (Pedrón-Torrecilla et al., 2016),
and/or the divergence/singularity points through phase mapping
(Haissaguerre et al., 2013, 2014). These drivers have been found
to be correlated to the ablated regions in patients with successful
outcome (Haissaguerre et al., 2013; Zhou et al., 2016) and are now
being targeted directly in clinical validation studies (Haissaguerre
et al., 2014; Knecht et al., 2017). While these studies indicate
these drivers are targeting the arrhythmogenic substrates, one
cannot rule out the possibility of false-positive errors. Technical
validation has demonstrated that coarse patterns of DF (seen
in Figure 6), singularity points, rotor/focal source density, etc.,
can all be accurately localized with ECGI (Modre et al., 2003;
Haissaguerre et al., 2014; Dubois et al., 2016; Figuera et al., 2016;
Metzner et al., 2017), but the specific ECGI features that most
effectively localize the arrhythmogenic substrate(s) in AT/AF are
still under debate. Pathological validation of this kind is nearly
impossible as often multiple ablations are performed during a
procedure, and it is unclear if all, some, or only the last locations
identified the true arrhythmogenic substrate(s). As such, indirect
clinical validation studies that show improved patient outcome or
reduced procedural times are currently the best option.
Arrhythmogenic Substrate Identification
for Ventricular Arrhythmias
As with atrial arrhythmias, one of the primary goals of ECGI is the
identification and understanding of arrhythmogenic substrates
for the onset and maintenance of ventricular tachycardia (VT)
and fibrillation (VF) to aid in treatment planning, e.g., to guide
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pharmacologic therapy, ICD implantation, or catheter ablation.
Below we outline the major areas ECGI has been used for
substrate identification in VT and/or VF.
Premature Ventricular Contraction
Patients with isolated and monomorphic PVCs or focal VT can
be treated by ablating the focal source of these arrhythmias, which
typically involves long, invasive electrophysiological mapping to
localize these ectopic activities. By non-invasively localizing the
arrhythmogenic site or at least estimating a region of interest
prior to the catheterization procedure, ECGI can provide a useful
presurgical guideline for the operator, and substantially improve
the planning of the procedure and thus reduce procedure
times (Potyagaylo et al., 2013), an example of such guidance
is demonstrated in Figure 7. Focal idiopathic VTs and PVCs
in the absence of structural heart disease are one of the
most well validated pathologies for ECGI application, as the
arrhythmogenic substrate is clearly defined and one can define
accuracy using a simple localization error (Schulze, 2015).
For example, a commercial implementation of ECGI (ECVUE,
CardioInsight, Cleveland, OH, United States) has been used
to localize PVCs (Erkapic and Neumann, 2015). Their ECGI
implementation localized the ventricle of origin (LV vs. RV)
correctly in 95.2% of the cases, compared to only 76.6% with 12-
lead ECG. Sub-localization within the ventricles was accurate in
95.2% of the cases with ECGI, compared to 38.1% with 12-lead
ECG. Ablation success was similar in both groups, both acutely
and at 3-month follow up. Failure of this ECGI implementation
(which uses an epicardial surface source model) to localize PVCs
occurred mainly in sites near the septum, especially at the LVOT
or RVOT (Erkapic and Neumann, 2015). In a study using NEEES
(EP Solutions SA, Yverdon-les-Bains, Switzerland), PVCs were
localized in 20 patients; in 86% of the cases, the correct ventricular
segment was diagnosed (Wissner et al., 2017). In a preliminary
study with nine participants, the Vivo 12-lead ECGI system
was able to successfully localize PVCs (defined as location of
successful ablation) in 86% of the cases, whereas human-based
12-lead ECG localization of PVC had a 27% accuracy (Gordon
et al., 2014).
Future validation would ideally compare old and new methods
to these previous works, potentially using a common and broad
data set to prevent bias. An international working group called
the Consortium for ECG Imaging (CEI1) has recently emerged
that seeks to enhance progress through collaboration and shared
data repositories [EDGAR (Aras et al., 2015)], with first results
very recently published (Svehlikova et al., 2018).
Scar Related Ventricular Tachycardia Mapping
Sustained reentrant VT (and VT-induced VF) is often formed
by narrow channels of surviving tissue inside a myocardial
scar. Catheter ablation is an effective treatment for scar-related
VT that modifies the scar substrate, for example by destroying
the tissue site at which the VT circuit exits the scar (exit
sites) [ESC Guidelines Management Ventr Arrh/AHA 2017
VA/SCD guideline (Reddy et al., 2007; Kuck et al., 2010; Sapp
1http://www.ecg-imaging.org/workgroups/pvc-localization
et al., 2016)]. These scar substrates are currently identified by
catheter mapping, either during artificially induced VTs (by
programmed electrical stimulation), in which the morphology
and critical components of the VT circuit can be delineated, or
during native rhythm where the region of myocardial scar and
potential critical sites can be identified from the characteristics
of the measured electrograms (although less specific than VT
mapping). However, these procedures can be hindered by a lack
of inducible arrhythmia or, more frequently, by the presence of
multiple inducible arrhythmias and the patients’ hemodynamic
intolerance to the induced VTs. Additionally, native-rhythm
substrate mapping involves invasive procedures with access often
limited to the left endocardium. ECGI, due to its non-invasive
nature, has the potential to augment catheter mapping in both
enabling instantaneous reconstruction of a single PVC or a brief
episode of VT and thus to provide non-invasive identification of
scar substrates during native rhythm. For VT mapping, a small
number of human studies have investigated the use of ECGI
to map the exit sites and activation pattern of reentry circuits,
using both epicardial ECGI (Wang et al., 2011; Sapp et al.,
2012; Zhang et al., 2012) and more recently using epicardial-
endocardial and 3D ECGI (Tsyganov et al., 2017; Wang et al.,
2018). For substrate mapping, while the use of ECGI to delineate
myocardial scar has been validated using MRI or voltage mapping
(Cuculich et al., 2011; Wang et al., 2013; Horácˇek et al., 2015),
studies are just emerging to examine its ability to reveal local
abnormal electrograms, such as fractionated electrograms, that
are suggestive of potential central pathways forming the VT
circuit (Wang et al., 2018). In all of these studies, a significant
challenge arises from the difficulty to establish the clinical ground
truth for the exit sites and central pathway for VT; as a result,
most existing validation studies are limited to qualitative or semi-
quantitative evaluations. Validation studies should focus on the
ability of ECGI to localize the VT exit site, using a similar metric
to validations based on PVCs, as well as other critical sites, such
as central pathways within myocardial scar.
Ventricular Fibrillation
Instantaneous whole-ventricle mapping systems such as ECGI
open the possibility to also investigate VF mechanisms, by
looking at focal centers or anchors of VF activity (similar to AF).
Results from this field are only just emerging (Frontera et al.,
2018) and could be validated with approaches that are similar to
those applied in the AF field, including answering the question of
whether these key spots within reentrant loops are really useful
targets for ablation.
Wolf-Parkinson White Syndrome
Wolff-Parkinson-White (WPW) syndrome involves a long-
standing altered activation sequence, different from normal sinus
rhythm, as a result of abnormal conductive cardiac tissue between
the atria and the ventricles that provides a pathway for a reentrant
tachycardia circuit. Similar to focal VT and PVCs, localization
of WPW is a natural application of for ECGI as a means to
guide catheter ablation. However, the high rate of success in
WPW using conventional approaches (Fitzpatrick et al., 1994)
and relatively minor potential for incremental clinical benefit has
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FIGURE 7 | Example of ECGI-guided ablation in a patient. Top: 12-lead ECG recorded during ECGI (white background) and clinical recording during symptoms (pink
background), both with a sinus beat and subsequent premature ventricular complex (PVC). Bottom: Live view as visible to the cardiologist-electrophysiologist during
the ablation procedure when using the Carto 3 cardiac mapping system. The 3D anatomy as determined by the Carto catheter (white structures) is overlaid with the
activation map of the PVC as created pre-procedurally with ECGI (red-to-blue: early-to-late activation time; blue dot: PVC origin). The cardiologist can use this live
view during the procedure to navigate the catheter to the area suspected of the PVC origin. Adapted with permission from: Cluitmans et al. (2016).
limited motivation to a few studies (Berger et al., 2006; Ghosh
et al., 2008).
Risk Stratification for Ventricular
Arrhythmias
In addition to identifying the arrhythmogenic substrate for
ventricular arrhythmias, ECGI has more recently been proposed
as a tool for risk stratification for arrhythmia, particularly VF
and sudden cardiac death. By imaging and quantifying the
important substrates for arrhythmia such as conduction and
repolarization abnormalities, ECGI may be used for screening
of the general public to identify those at risk. Initial studies
have begun to identify these potential arrhythmogenic substrates,
such as the presence of slow discontinuous conduction and steep
dispersion of repolarization in the RVOT of Brugada patients
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(Zhang et al., 2015), the presence of repolarization abnormalities
in ARVC patients (Andrews et al., 2017), steepness of recovery
gradients (Vijayakumar et al., 2014), and recovery substrates in
sudden cardiac death survivors (Leong et al., 2017). However,
much work is still needed in this area not only to confirm these
substrates but also to develop and validate risk stratification
markers that identify them and to demonstrate clinical utility.
Heart Failure and Cardiac
Resynchronization Therapy
Cardiac Resynchronization Therapy (CRT) through biventricular
pacing can improve outcomes in patients with heart failure and
with low ejection fraction. However, the effect varies widely with
approximately a third of patients failing to respond. To improve
CRT response rates, recommendations emphasize attention to
low resolution electrical parameters from the 12-lead ECG (i.e.,
left bundle branch block and QRS duration ≥150 ms). However,
detailed understanding of the spatiotemporal excitation pattern
in the failing human heart and its relationship to a CRT response
are lacking. ECGI has been used to fill some of this gap,
providing new insights into the electrical substrates specific
to responders (Varma et al., 2007; Berger et al., 2011; Ghosh
et al., 2011; Ploux et al., 2013), including abnormal activation
patterns with slow conduction and/or line of block and electrical
dyssynchrony, both within and between the ventricles. With
knowledge of these substrates, new ECGI-derived criteria have
been developed, demonstrating improved responder selection
compared to the current standard metrics (Ploux et al., 2013).
Clinical validation of these metrics in the form of large-scale
multi-center trials is still required to demonstrate that these
metrics are capturing the correct electrical substrates. Technical
validation has demonstrated that the presence of functional
lines of block seen clinically in these patients may in fact
be an artifact of ECGI (Bear et al., 2018a) (see Figure 4).
Despite this, ECGI has reliably and accurately detected electrical
dyssynchrony, resynchronization by biventricular pacing, and
the site of latest activation, providing more information than
the 12-lead ECG. Further validation of ECGI methods in the
presence of heart failure and/or electrical dyssynchrony could
improve reconstructions to remove these artifacts and increase
the sensitivity and specificity of these markers, and possibly to
develop methods for targeted left ventricular lead placement.
CLINICAL (AND SOCIOECONOMIC)
VALIDATION
Electrocardiographic imaging validation studies in the past have
typically focused on the technical or pathological validation and
until recently, large-scale studies using ECGI clinically have not
been possible. With the commercialization of ECGI systems, their
use on a large scale in hospitals worldwide is now a possibility. As
such, this section will deal with the need for studies to address
the actual clinical benefit in terms of personalized understanding
of disease mechanisms and its potential to open new avenues
for therapy, improved patient outcome, and improved workflow.
As far as we know, the following systems are currently in
development for commercial purposes: the CardioInsightTM
Noninvasive 3D Mapping System (Medtronic), the Non-Invasive
Electrophysiological Mapping (NIEM) system (EP Solutions SA),
and the View Into Ventricular Onset (Vivo) system (Peacs,
Catheter Precision).
Clinical Application Domains
The potential applications of ECGI (and their validation)
fall into three major categories: (1) Personalized disease
understanding and diagnosis; (2) Therapy guidance; and (3)
Enabling innovations.
Personalized Disease Understanding
Many of the studies discussed in section “Pathological Validation”
have investigated disease mechanisms with ECGI and proposed
parameters that carry relevant clinical information. For example,
ECGI has been used to uncover repolarization gradients that
are more pronounced in symptomatic than asymptomatic LQTS
patients (Vijayakumar et al., 2014). Similarly, the more detailed
information provided by ECGI has demonstrated the presence
of larger ventricular electrical dyssynchrony in CRT responders
providing improved CRT patient selection compared to standard
12-lead ECG (Varma et al., 2007; Ploux et al., 2013). These
retrospective studies are important to help understand the
underlying disease mechanisms and define the parameters or
markers that may guide therapy. But to fully demonstrate that
this information carries value for an individual patient and could
guide therapy or patient selection requires further investigations
using large-scale prospective studies.
Therapy Guidance
Most clinical studies have aimed at using ECGI for therapy
guidance. To date the focus has been on demonstrating a
decrease in radiofrequency ablation and procedural times for
atrial arrhythmia substrates or PVC origin ablation therapy, as
pathological studies, discussed in sections “Atrial Arrhythmias”
and “Premature Ventricular Contraction,” have shown that
accurate localization of these substrates is feasible. A clinical
validation study for AF has reported that using ECGI to identify
ablation targets with phase mapping, as seen in Figure 6,
significantly reduced radio-frequency delivery (28 ± 17 vs.
65 ± 33 min) and thus procedure times for successful outcome,
compared to standard methods (Haissaguerre et al., 2014).
Likewise, for PVC localization, clinical validation has shown the
number of radiofrequency energy applications was significantly
lower in the group with CardioInsight-based localization (two
applications) in comparison with the control group (four
applications) and procedure times were shorter (Erkapic and
Neumann, 2015).
In order to be used in other pathologies, it is necessary
to overcome technical challenges that currently limit the
applicability of ECGI during invasive cardiac procedures
(e.g., the need to integrate defibrillation patches and 3-
dimensional mapping systems). ECGI might then guide therapy
by characterizing electrical substrate(s) in more detail than is
possible from the 12-lead ECG. For example, ECGI provides
detailed electrical activation patterns of the left (LV) and
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right ventricle (RV), which could guide CRT implantation by
suggesting the optimal placement of the LV lead (Ploux et al.,
2014; Bear et al., 2018a). ECGI may also enable risk stratification
and guide ICD implantation for sudden cardiac death by
imaging of activation and recovery abnormalities, both important
arrhythmogenic substrates (Vijayakumar et al., 2014).
For all of these applications, prospective clinical trials are also
needed to validate the clinical benefit. ECGI for AF is leading
the way, with one such multi-center trial currently underway
(AFACART2) aiming to evaluate the effectiveness of ECGI for
persistent AF mapping and ablation procedures in comparison
to conventional methods. Initial results recently published from
this trial have demonstrated a persistent AF termination success
of 72% (n = 118), with no significant difference among the 8
European centers in the study (Knecht et al., 2017).
Enabling Innovative Therapies
Electrocardiographic imaging carries the potential to permit
new and innovative therapies. A recent study has demonstrated
the feasibility of combining ECGI with non-invasive delivery
of ablative radiation, suggesting that clinicians may be able to
completely non-invasively target VT substrate with radiotherapy
(Cuculich et al., 2017). Accurate identification and localization
of arrhythmogenic myocardial substrate could facilitate further
progress in the development of safe, effective therapeutic
interventions.
Furthermore, studies are currently investigating the used of
ECGI with tagged MRI/CT or speckle-tracking echocardiography
(Dawoud et al., 2016). Combining non-invasive imaging of
electrical and mechanical function and their interaction in situ
could provide new insights that would be extremely valuable
for characterization of disease mechanisms and development
of treatment strategies. The wealth of information provided by
ECGI, and its non-invasive nature, might open the door to more
novel innovations.
Demonstration of Added Clinical Value
Improved Patient Outcome
One obvious goal of clinical validation studies is to show that
ECGI can improve patient outcome. This requires long-term,
large-scale (thus expensive) clinical trials to validate the findings
arising from small scale technical or pathological validation
studies; one such example is the AFACART study. These types
of studies are needed to prove patient benefit in terms of
reduced recurrence rates after such ECGI-guided procedures as
PVC ablation (Erkapic and Neumann, 2015) and AF ablation
(Haissaguerre et al., 2014) or improved CRT patient selection or
lead positioning (Ploux et al., 2013). There are many potential
reasons why ECGI may not improve patient outcome including:
(1) a lack of understanding of disease mechanisms, making it
difficult to specify how ECGI could prove useful (e.g., rotors in
AF or lack of response in CRT); (2) the lack of clinical need
(PVC ablation can often be performed without expensive or
complex mapping systems); and (3) the preliminary nature of
many studies seeking to show ECGI results prior to randomized
2https://clinicaltrials.gov/ct2/show/NCT02113761
control trials. Large, multi-center studies are currently being
designed or are underway to investigate the benefit of ECGI for
various diagnostic and therapeutic purposes.
Improved Workflow and Reduced Cost
Another improvement that could be provided by ECGI is
in workflow and (socio)economic cost. Such benefits are
particularly important if ECGI is to be considered as a
tool for risk stratification and general population screening.
The associated validation studies should focus on finding
the optimal balance between time and financial investment
(ECGI is more expensive and more time-consuming than a
standard ECG) vs. benefit for society. These benefits could
include: lower hospitalization rates with AF and VT ablation,
shorter procedural times (or lower variability of procedure
results, making hospital planning more reliable), socioeconomic
benefit due to improved patient selection for ICD therapy,
etc. Commercial implementations of ECGI are essential for
this and preferably include regulatory approval and financial
reimbursement. To our knowledge, Medtronic’s CardioInsight
system is the only FDA-approved ECGI implementation, and no
ECGI implementation is currently being reimbursed by health
care insurers.
Clinical Adoption
Clinical adoption of ECGI depends critically on technical,
pathological and clinical validation, but also on practicability,
demonstration of cost-effectiveness, and appropriate
reimbursement mechanisms. Additionally, if levels of
confidence or uncertainty were reported to clinicians for
ECGI reconstructions in individual cases (taking into account
levels of noise, defective electrodes, regions that are hard to
reconstruct, etc.) it might further improve clinical reliance on
ECGI results. In general it is not yet clear what is the best context
to apply ECGI to improve health care, and it is important to
realize that while such benefits might lie in improved diagnosis,
therapy guidance, or patient outcome, they may also result
from improved workflow (reduction of procedural times, less
variability in procedure duration) and reduced cost (shorter
or fewer hospitalizations). Whatever the focus, such studies
will cost time and money and will benefit from focused clinical
applications.
CONSENSUS ON DESIGNING A
VALIDATION STUDY
In designing and presenting a validation study, there are
many choices that can have a large impact of the validity
of the results. In this section, we provide a consensus on
the “best” approaches. This consensus is based on discussions
among the authors at recent conferences (Computing in
Cardiology [CinC] 2015–2017; Frontiers in Computational
Electrocardiology [FiCE] 2016; and the International Society for
Computerized Electrocardiology [ISCE] conference 2015), and
during other meetings.
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Data Selection
Data sets come in various forms: simulated, experimental (ex vivo
torso tank or in vivo animal model), and clinical as summarized in
Macleod and Brooks (2000). The ideal validation would include
data in more than one form (i.e., simulated and experimental),
and include multiple sources (i.e., multi-institutional clinical
and/or experimental data). Depending on a single data set can
lead to algorithms becoming biased or tuned to these data and
ultimately failing on other independent data. Validation using
in vivo animal and clinical models are particularly needed to
address the technical questions surrounding accuracy, feasibility,
and reliability. Using data from multiple sources/forms adds to
the rigor, reliability, and reproducibility of the results.
However, obtaining such data sets is often impossible for
individual labs due to the large costs and/or lack of available
facilities. Collaborative efforts have and will continue to help
overcome this problem. To enable such projects, an international
consortium has created an open platform for sharing data,
which is populated with datasets (14 datasets from 8 different
centers as of the submission of this manuscript). This database is
called the Experimental Data and Geometric Analysis Repository
(EDGAR3) and is hosted at the University of Utah, as described
in Aras et al. (2015). EDGAR has already supported a number
of cross-laboratory validation studies published in both journals
and relevant conferences (Chamorro-Servent et al., 2016;
Schulze et al., 2017; Cluitmans et al., 2018; Svehlikova et al.,
2018).
An essential requirement for the data sets of choice is to define
an appropriate ground truth, a goal that as described above is not
always easy with experimental or clinical data. We recommend
including the error of experimentally determined “ground truth”
whenever possible, to give context to validation studies, e.g., the
accuracy in localization of an ablation site.
Technical, Pathological or Clinical
Validation
Despite the distinction between technical, pathological, and
clinical validation in this review, in practice validation should
be seen more as existing on a continuum (see Figure 1). In
the early days, validation studies of a purely technical nature
were common, but with time, studies have included pathological
aspects; however, there are still only few published purely
clinical/socioeconomical validation studies. Given the increased
application of ECGI for clinical use, future validation studies
should contain aspects of at least two forms of validation,
if not all three, by giving a clinically oriented perspective to
results. For example, validation of a new formulation for ECGI
in a purely technical fashion might report that electrograms
are now reconstructed with a correlation slightly better than
previously reported methods. However, putting this result into
perspective in terms of quantifying, say, improved accuracy to
detect arrhythmogenic substrate for ablation targeting, and/or




To assess ECGI accuracy in technical validation studies, a variety
of metrics have been derived and reported. Each metric comes
with its own advantages and disadvantages, supporting the use of
several different metrics to carry out a useful evaluation. Here, we
discuss these metrics, their current uses and their limitations.
Global Comparisons
In general, it is important to quantify accuracy in both time
and space in a global sense; to quantify similarity in shape (e.g.,
temporal waveforms or spatial potential/activation distributions),
and amplitude (e.g., voltage). Metrics to quantify global accuracy
include:
• Correlation: this metric is often used in ECGI validation
as it quantifies the accuracy in shape regardless of any
amplitude inaccuracies. However, it may not be clear
to clinicians what the different values of correlation
correspond to in terms of diagnostic or therapeutic
accuracy. For example, electrode 5 in Figure 3 shows a
high correlation coefficient that does not reflect the fact
that the reconstructed electrogram misses the (clinically
informative) initial positive deflection shown by the ground
truth.
• Phase Locking Value (PLV): PLV estimates the average
synchronicity between two signals, without regard to the
constant phase shift between them (Dubois et al., 2016).
This is useful in the evaluation of phase, where the exact
synchronicity of the signals is less important.
• Relative or Absolute Error: these metrics are used to
quantify the accuracy in amplitude (or timing in the case
of activation maps). Relative error has the advantage of
defining the accuracy relative to the size of the feature
being measured, meaning it can be more clear whether
an absolute difference is very significant or not (e.g., an
absolute error of 2 mV is not very important when the
gold standard is 25 mV, but more substantial when it
is 4 mV). However, like correlation, relative error is less
meaningful to clinicians. Furthermore, relying on relative
error can badly miss critical similarities, e.g., a slight time
misalignment of activation could result in a large value of
squared error. Conversely, small abnormalities (e.g., a small
infarcted region or scar) that are missed in a reconstruction
may not significantly affect global relative error.
Local Comparisons
As discussed previously, correlation and/or relative/absolute
error correspond to accuracy on a global scale (Figures 3–5),
but neglect the accuracy of the finer, potentially more important,
characteristics. The following metrics have been developed to
quantify the accuracy of specific characteristics.
• Localization Error: this metric is used to define the accuracy
in localization of specific features (e.g., in space: site of
earliest activation; or in time: timing of first breakthrough).
While it is easy to interpret, it is not always the most
clinically relevant metric. For example, a 5 mm error in
PVC localization is more significant than a much larger
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error in distance, if the location is incorrectly identified
as the LV instead of the RV compared to when both
correct and incorrect sites are in the same chamber.
Some authors have quantified localization to a predefined
segment of the heart [e.g., segmentation according to
the AHA classification (Austen et al., 1975)] but these
indicators can also be misleading, for example if the correct
location lies just on one side of a segment boundary and the
reconstructed location is nearby but just on the other (Sapp
et al., 2017). Moreover, estimation of activation time and
site of first activation from reconstructed electrograms is
itself a difficult problem that is currently the topic of active
investigation by many groups (Erem et al., 2011; Duchateau
et al., 2016), including the CEI workgroup on Activation
and Recovery times4.
• Weighted under/over-estimation indicators (Figuera et al.,
2016): are used to assess the localization accuracy of larger
features such as the divergence/singularity points maps or
ischemic region detection. They define the percentage of
misjudged region (either positive or negative), by the ECGI
reconstruction. These indicators are highly dependent on
the size of the region being assessed, and like relative error
can miss critical similarities if the region reconstructed is
only slightly misaligned.
While each metric has its merits, the limitations mean it is
advisable to use all of these metrics with caution and ideally
none should be the only metric used in a technical validation
study. That is, for each feature, other clinically relevant, ideally
quantitative, comparisons are necessary. These should be based
on the characteristics of each feature one wants to reconstruct,
e.g., electrogram fractionation, ST-segment elevation, DF or
phase singularity points, etc.
Given the sensitivity of inverse reconstructions to noise and
model error (which could well be from physiological causes
such as respiratory or contractile motion), studies should report
the distribution of cumulative results across an ensemble of
beats, and not just a single case or a mean reconstruction.
For example, box plots showing the median, the quartiles and
outliers can be a better choice. More broadly, new metrics
will likely need to continue to be developed to achieve these
goals.
Reproducibility
A thorough description of all experiments and analyses is
essential to allow for reproducibility and reliable comparison to
other methods. Such descriptions include the full workflow, from
scanner settings to segmentation to therapy application to metric
calculation. Clinical study design should be fixed before being
executed and registered publicly (e.g., ClinicalTrials.gov). The
investigators may also choose to share the data and/or methods
used (e.g., via collaboration or the EDGAR database), allowing




The statistical analysis performed for any validation study
depends on the form of validation, comparisons made, data set
used, and many other factors. The choice of statistical test must be
made with care. Unfortunately, many studies use a simple t-test,
missing potentially important information that may be obtained
by taking into account other dependent and independent factors
that can influence accuracy (e.g., subject, cardiac sequence, or
region of the heart for reconstruction), as well as by including
comparisons based on carefully designed metrics of effect size
as well as on more comprehensive distributional comparisons.
Incorporating these factors into the analysis may help reveal
the source of outliers, define regional accuracy, or provide an
indication of confidence in the results. In particular, including
effect size in addition to the more traditional mean or median-
based statistics allows the evaluation of the clinical relevance
of statistically significant differences, i.e., outcomes may fall in
statistically significantly different groups, based on means or
median, but overlap of distribution between those groups may
prevent reliable prediction on a per-patient level.
THE FUTURE OF ECGI
Electrocardiographic imaging has a rich history, from the first
model development and animal studies in the 1970s, through
extensive technical validation studies in computer simulations,
ex vivo torso tank and in vivo animal studies, to its more
recent human use to understand pathological mechanisms of
diseases and guide clinical procedures in patients. Continued
technical, pathological, and especially clinical validation will be
essential for full adoption of ECGI as clinical technique. We
have highlighted the accomplishments of the last decades, and
have given pointers to what remains to be done for specific
diseases and applications. Specifically, showing clinical benefit
is essential for the adoption of this powerful technique. Such
benefit may lie in patient outcome improvement, workflow
improvement, or cost reduction. Future studies should focus
on these aspects to achieve broad adoption of ECGI, but only
after the technical challenges have been solved for that specific
application/pathology. Importantly, one should realize that ECGI
remains a tool used for one half of patient treatment, with
the other half being the therapy given. If the therapy itself
is inadequate or incomplete, it should be no surprise that
the application of ECGI will not directly improve procedure
outcome. Similarly, if disease mechanisms are not completely
understood, the therapeutic value of ECGI-detected substrate is
limited. Continued interaction between engineers, basic scientists
and physicians remains essential to find a hybrid between
technical achievements, pathological mechanisms insights, and
clinical benefit.
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